ArticleBMC cancer2026
Predicting prognosis and drug sensitivity in patients with hepatocellular carcinoma using an lncRNA signature associated with cuproptosis.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is a prevalent type of malignant tumor known for its aggressive proliferation and invasive behavior. The exact molecular mechanisms underlying HCC development and progression remain unclear. Nevertheless, cuproptosis has been linked to a range of diseases, including cancers, resulting from imbalances in copper homeostasis. Here, a unique signature of long non-coding RNAs (lncRNAs) was developed, known as cuproptosis-related lncRNA (CRlncRNA). This signature has significant value in clinical practice for predicting prognosis and drug sensitivity in individuals with HCC.
methodsThe transcriptome data and clinical information were retrieved from the Cancer Genome Atlas (TCGA) database. The independent prognostic signature of five CRlncRNAs was constructed by co-expression analysis, Lasso Cox regression analysis, and univariate and multivariate Cox regression analysis. K-M analysis and ROC curve were used to evaluate the effectiveness of the signature in predicting prognosis and IC50 was used to predict the sensitivity of drugs. Furthermore, the differential expression of five CRlncRNAs was validated in clinical HCC samples, and functional in vitro experiments were performed to investigate the biological role of LINC02505, which is one of the five CRlncRNAs.
resultsBased on 374 HCC samples, a prognostic risk signature of five lncRNAs was constructed. High-risk patients showed significantly decreased survival periods, indicating that the CRlncRNA signature has predictive value in HCC. Combined with clinical and pathological information, the signature was shown to be an independent prognostic factor. Besides, the CRlncRNA signature was found to be closely associated with the efficacy of many commonly used chemotherapy drugs and targeted drugs for HCC patients. Additionally, further investigations showed that the mutation rate of HCC was related to the CRlncRNA signature, and gene enrichment analysis focused on immune-related pathways. Finally, among the CRlncRNA signature, LINC02505 was tested as a risk factor in vitro.
conclusionsThe CRlncRNA signature has significant clinical implications as it offers new biomarkers for evaluating HCC prognosis and guiding clinical medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.